Treatment of Helicobacter Pylori infection in patients with dyspepsia

Comparison of three therapeutic regimens (Rabiprazole, Amoxicillin, Bismuth subcetate, Clarithromycin (1), Rabiprazole, Amoxicillin, Clarithromycin (2) Rabiprazole, Amoxicillin, Bismuth subcetate, Furazolidone (3)) in eradication of Helicobacter pylori in

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160318027097N6

Enrollment

Registered

2017-12-12

Start date

2017-12-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspepsia. Dyspepsia

Interventions

Intervention 1: Case group (2): Rabiprazole, Tablet 40mg oral OD for 6 weeks. Amoxicillin, Tablet 1000mg oral BD for 2 weeks. Clarithromycin, Tablet 500mg oral BD for 2 weeks. Intervention 2: Case gro

Treatment - Drugs

Case group (2): Rabiprazole, Tablet 40mg oral OD for 6 weeks. Amoxicillin, Tablet 1000mg oral BD for 2 weeks. Clarithromycin, Tablet 500mg oral BD for 2 weeks

Case group (3): Rabiprazole, Tablet 40mg oral OD for 6 weeks. Amoxicillin, Tablet 1000mg oral BD for 2 weeks. Bismuth subcitrate, Tablet 120mg oral BD for 2 weeks. Furazolidone Tablet 200mg oral BD fo

Case group (1): Rabiprazole, Tablet 40mg oral OD for 6 weeks. Amoxicillin, Tablet 1000mg oral BD for 2 weeks. Bismuth subcitrate, Tablet 120mg oral BD for 2 weeks. Clarithromycin Tablet 500mg oral BD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Endoscopic and biopsied patients; Report of the Helicobacter pylori organism in the tissue sample.

Exclusion criteria

Exclusion criteria: Pregnancy; Intolerance to drugs; Interaction with medications such as digoxin; drug complications during treatment.

Design outcomes

Primary

Measure	Time frame
Fecal antigen of Helicobacter pylori. Timepoint: 4 weeks after Intervention. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoud Tasoji

Ardebil University of Medical Sciences

naghizadeh73@yahoo.com+98 45 3351 2006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026